Abstract
The excitation/inhibition (E/I) ratio has been shown to be elevated in both autism spectrum disorder (ASD) and schizophrenia (SZ), relative to neurotypical controls. However, the degree of E/I imbalance overlap and differentiation between SZ and ASD is not known. Our main objectives were therefore (1) to quantify group differences in the E/I ratio between controls, ASD and SZ, and (2) to assess the potential of the E/I ratio for differential diagnosis. We collected resting state fMRI (rsfMRI) and phenotypic data from 55 controls, 30 ASD, and 39 SZ, ages 18 to 35 (IQ>80). For each participant, we computed the Hurst exponent (H), an indicator of the E/I ratio, for the timecourses of 53 independent components covering the entire brain. Next, using Optimal Classification Trees (OCT), we ran a classification analysis on the two clinical groups using five incremental feature sets (i.e., models): (1) Positive and Negative Syndrome Scale (PANSS) and the Autism Diagnostic Observation Schedule (ADOS) only; (2) PANSS, ADOS, Bermond–Vorst Alexithymia Questionnaire (BVAQ), Empathy Quotient (EQ), and IQ; (3) H only; (4) H, PANSS and ADOS; (5) H, PANSS, ADOS, BVAQ, EQ and IQ. We observed decreased H (i.e., increase in E/I ratio) in ASD and SZ compared to controls, and in SZ compared to ASD in the Cerebellar, Sensorimotor, Visual and Cognitive Control networks. The OCT classification showed a consistent increase in discrimination accuracy across models between ASD and SZ, suggesting that the E/I ratio in combination with phenotypic measures can contribute to differential diagnosis in adults.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health (R01 MH095888 and R01 MH119069; M. Assaf) and the National Alliance for Research in Schizophrenia and Affective Disorders (Young Investigator Award 17525; S. Corbera)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board at the Institute of Living and Yale Medical School has approved the data collection of the current study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Most of the data in the current study has already been submitted to the NDAR public repository.
